Quercetin alleviates myocyte toxic and sensitizes anti-leukemic effect of adriamycin

References

• Kilari D, Venci N, Friedberg J, Bennett JM. Hemophagocytic lymphohistiocytosis masquerading as progressive chronic lymphocytic leukemia. Leuk Res Rep. 2013;2(1):4–6.
   PubMedGoogle Scholar
• Kodidela S, Suresh Chandra P, Dubashi B. Pharmacogenetics of methotrexate in acute lymphoblastic leukaemia: why still at the bench level? Eur J Clin Pharmacol. 2014;70(3):253–260.
   PubMed Web of Science ®Google Scholar
• Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2013;380(9859):2095–128.
   Web of Science ®Google Scholar
• Eichhorst BF, Busch R, Hopfinger G, Pasold R, Hensel M, Steinbrecher C, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006;107(3):885–91.
   PubMed Web of Science ®Google Scholar
• Gribben JG. Stem cell transplantation in chronic lymphocytic leukemia. Biol Blood Marrow Transplant. 2009;15(1):53–8.
   PubMed Web of Science ®Google Scholar
• Laginha KM, Verwoert S, Charrois GJ, Allen TM. Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors. Clin Cancer Res. 2005;11(19):6944–9.
   PubMed Web of Science ®Google Scholar
• Fornari FA, Randolph JK, Yalowich JC, Ritke MK, Gewirtz DA. Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells. Mol Pharmacol. 1994;45(4):649–56.
   PubMed Web of Science ®Google Scholar
• Pommier Y, Leo E, Zhang H, Marchand C. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol. 2010;17(5):421–33.
   PubMed Web of Science ®Google Scholar
• Tan C, Tasaka H, Yu KP, Murphy ML, Karnofsky DA. Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia. Cancer. 1967;20(3):333–53.
   PubMed Web of Science ®Google Scholar
• Lefrak EA, Pit'ha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer. 1973;32(2):302–14.
   PubMed Web of Science ®Google Scholar
• Chen J-Y, Hu R-Y, Chou H-C. Quercetin-induced cardioprotection against doxorubicin cytotoxicity. J Biomed Sci. 2013;20(1):95.
   PubMed Web of Science ®Google Scholar
• Verschoyle RD, Steward WP, Gescher AJ. Putative cancer chemopreventive agents of dietary origin – how safe are they? Nutr Cancer. 2007;59(2):152–62.
   PubMed Web of Science ®Google Scholar
• Murakami A, Ashida H, Terao J. Multitargeted cancer prevention by quercetin. Cancer Lett. 2008;269(2):315–25.
   PubMed Web of Science ®Google Scholar
• Nöthlings U, Murphy SP, Wilkens LR, Henderson BE, Kolonel LN. Flavonols and pancreatic cancer risk the multiethnic cohort study. Am J Epidemiol. 2007;166(8):924–31.
   PubMed Web of Science ®Google Scholar
• Tachibana H, Koga K, Fujimura Y, Yamada K. A receptor for green tea polyphenol EGCG. Nat Struct Mol Biol. 2004;11(4):380–1.
   PubMed Web of Science ®Google Scholar
• Li M, He Z, Ermakova S, Zheng D, Tang F, Cho Y-Y, et al. Direct inhibition of insulin-like growth factor-I receptor kinase activity by (−)− epigallocatechin-3-gallate regulates cell transformation. Cancer Epidemiol Biomarkers Prev. 2007;16(3):598–605.
   PubMed Web of Science ®Google Scholar
• Ermakova S, Choi BY, Choi HS, Kang BS, Bode AM, Dong Z. The intermediate filament protein vimentin is a new target for epigallocatechin gallate. J Biol Chem. 2005;280(17):16882–90.
   PubMed Web of Science ®Google Scholar
• Denison MS, Pandini A, Nagy SR, Baldwin EP, Bonati L. Ligand binding and activation of the Ah receptor. Chem Biol Interact. 2002;141(1):3–24.
   PubMed Web of Science ®Google Scholar
• Denison MS, Nagy SR. Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. Ann Rev Pharmacol Toxicol. 2003;43(1):309–34.
   PubMed Web of Science ®Google Scholar
• Rietjens IM, Boersma MG, van der Woude H, Jeurissen SM, Schutte ME, Alink GM. Flavonoids and alkenylbenzenes: mechanisms of mutagenic action and carcinogenic risk. Mutat Res FundamMol Mech Mutagen. 2005;574(1):124–38.
   PubMed Web of Science ®Google Scholar
• van der Woude H, Alink GM, van Rossum BE, Walle K, van Steeg H, Walle T, et al. Formation of transient covalent protein and DNA adducts by quercetin in cells with and without oxidative enzyme activity. Chem Res Toxicol. 2005;18(12):1907–16.
   PubMed Web of Science ®Google Scholar
• Neuhouser ML. Review: dietary flavonoids and cancer risk: evidence from human population studies. Nutr Cancer. 2004;50(1):1–7.
   PubMed Web of Science ®Google Scholar
• Paliwal S, Sundaram J, Mitragotri S. Induction of cancer-specific cytotoxicity towards human prostate and skin cells using quercetin and ultrasound. Br J Cancer. 2005;92(3):499–502.
   PubMed Web of Science ®Google Scholar
• Xavier CP, Lima CF, Rohde M, Pereira-Wilson C. Quercetin enhances 5-fluorouracil-induced apoptosis in MSI colorectal cancer cells through p53 modulation. Cancer Chemother Pharmacol. 2011;68(6):1449–57.
   PubMed Web of Science ®Google Scholar
• Hoetelmans R. Nuclear partners of Bcl-2: Bax and PML. DNA Cell Biol. 2004;23(6):351–4.
   PubMed Web of Science ®Google Scholar
• Cleary ML, Smith SD, Sklar J. Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t (14; 18) translocation. Cell 1986;47(1):19–28.
   PubMed Web of Science ®Google Scholar
• Livolsi A, Busuttil V, Imbert V, Abraham RT, Peyron JF. Tyrosine phosphorylation-dependent activation of NF-κB. Eur J Biochem. 2001;268(5):1508–15.
   PubMedGoogle Scholar
• Sheikh MS, Huang Y. Death receptor activation complexes: it takes two to activate TNF receptor 1. Cell Cycle. 2003;2(6):549–51.
   Web of Science ®Google Scholar
• Minami M, Matsumoto S, Horiuchi H. Cardiovascular side-effects of modern cancer therapy. Circ J. 2010;74(9):1779–86.
   PubMed Web of Science ®Google Scholar
• Xi L, Zhu S-G, Das A, Chen Q, Durrant D, Hobbs DC, et al. Dietary inorganic nitrate alleviates doxorubicin cardiotoxicity: mechanisms and implications. Nitric Oxide. 2012;26(4):274–84.
   PubMed Web of Science ®Google Scholar
• Rice-Evans CA, Miller NJ, Paganga G. Structure-antioxidant activity relationships of flavonoids and phenolic acids. Free Radic Biol Med. 1996;20(7):933–56.
   PubMed Web of Science ®Google Scholar
• Brown J. A review of the genetic effects of naturally occurring flavonoids, anthraquinones and related compounds. Mutat Res Rev Genetic Toxicol. 1980;75(3):243–77.
   PubMed Web of Science ®Google Scholar
• Macgregor JT, Jurd L. Mutagenicity of plant flavonoids: structural requirements for mutagenic activity in Salmonella typhimurium. Mutat Res Environ Mutagen Relat Subj. 1978;54(3):297–309.
   PubMed Web of Science ®Google Scholar